Beam Therapeutics
Beam Therapeutics' revenue rose 120.0% to $140 million in fiscal 2025. Its operating margin was −274.6%, up from −654.2% a year earlier. Free cash flow was −$360 million. The diluted share count rose 20.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Beam Therapeutics does
Beam Therapeutics is a biotechnology company that develops gene-editing medicines. Its technology, called base editing, changes a single letter of DNA without cutting both strands of the DNA. The company also builds its own delivery technologies and has its own manufacturing. It has never sold a product.
Its lead program, risto-cel, is a treatment made from a patient's own stem cells to treat sickle cell disease. The company says it could file for approval as early as the end of 2026. Another program, BEAM-302, is a one-time treatment for alpha-1 antitrypsin deficiency, a genetic liver and lung disease. It also has programs for phenylketonuria and glycogen storage disease type 1a.
Beam has no product revenue and says it expects losses for the foreseeable future. It has a financing agreement with Sixth Street Lending Partners and says it will need more funding.
Its biggest risks, as it describes them
- It has lost money since it began and may never be profitable.
- It will need more funding, which could dilute shareholders or limit its operations.
- It has never earned revenue from product sales.
- Base editing is a new technology and may never lead to products it can sell.
- Clinical trials may be delayed or fail, and early results may not predict later ones.
Income statement
Beam Therapeutics lost money in fiscal 2025: a net loss of $80 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 966 | 1,100 | 1,200 | 851 | 1,200 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −692.2x | −900.2x | −1,103.0x | −12,986.5x | — |
| Current ratio | 6.0x | 4.9x | 5.9x | 4.8x | 13.1x |
| Quick ratio | 6.0x | 4.9x | 5.9x | 4.8x | 13.1x |
Cash flow
Projections
Project Beam Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Beam Therapeutics shares on the open market, and 7 insiders sold $18.5 million, $8.5 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | Amy SimonChief Medical Officer | Sold plan | 16,667 | $25.74 | $429,009 | Form 4 |
| Jun 30, 2026 | John M. EvansCEO, Director | Sold plan | 25,000 | $34.30 | $857,602 | Form 4 |
| Jun 30, 2026 | Amy SimonChief Medical Officer | Sold plan | 373 | $34.73 | $12,954 | Form 4 |
| Jun 29, 2026 | John M. EvansCEO, Director | Sold plan | 25,000 | $35.49 | $887,282 | Form 4 |
| Jun 26, 2026 | Fmr Llc10% owner | Sold | 251,488 | $35.26 | $8.9 million | Form 4 |
| Jun 25, 2026 | Fmr Llc10% owner | Sold | 33,372 | $35.12 | $1.2 million | Form 4 |
| Apr 1, 2026 | John M. EvansCEO, Director | Sold plan | 30,078 | $24.58 | $739,317 | Form 4 |
| Apr 1, 2026 | Giuseppe CiaramellaPresident | Sold plan | 11,810 | $24.58 | $290,290 | Form 4 |
| Apr 1, 2026 | Amy SimonChief Medical Officer | Sold plan | 6,700 | $24.58 | $164,686 | Form 4 |
| Apr 1, 2026 | Christine BellonChief Legal Officer | Sold plan | 5,956 | $24.58 | $146,398 | Form 4 |
| Apr 1, 2026 | Bethany J CavanaghSVP, Finance and Treasurer | Sold plan | 3,242 | $24.58 | $79,688 | Form 4 |
| Mar 31, 2026 | John M. EvansCEO, Director | Sold plan | 25,000 | $22.76 | $569,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 471.6% | −644.0% | −137.6% |
| Altman Z'' | 3.20 | −0.94 | 5.19 |
| Accruals ratio | 1.2% | −2.3% | 20.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Beam Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics | FY25 | 120.0% | −274.6% | −257.6% | — | — | — | |
| Xencor | FY25 | 13.7% | −141.3% | −110.1% | −19.9% | — | 3 | Compare |
| Monte Rosa Therapeutics | FY25 | 63.5% | −43.8% | −22.2% | — | — | — | Compare |
| Regenxbio | FY25 | 104.5% | −94.6% | −74.2% | — | — | — | Compare |
| ImmunityBio | FY25 | 668.3% | −226.0% | −272.6% | — | — | 3 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0 | 0 | 52 | 61 | 378 | 64 | 140 |
| Revenue growth | — | 33.3% | 215,916.7% | 17.5% | 520.0% | −83.2% | 120.0% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 55 | 103 | 387 | 312 | 437 | 368 | 410 |
| Operating income | −75 | −133 | −392 | −338 | −176 | −416 | −384 |
| Net income | −78 | −195 | −371 | −289 | −132 | −377 | −80 |
| Diluted EPS (US$) | −14.05 | −4.19 | −5.77 | −4.13 | −1.72 | −4.58 | −0.81 |
| Diluted shares (millions) | 6 | 47 | 64 | 70 | 77 | 82 | 99 |
| Cash flow | |||||||
| Cash from operations | −72 | −96 | −66 | 22 | −149 | −347 | −345 |
| Capital expenditure | 12 | 16 | 47 | 49 | 34 | 9 | 15 |
| Free cash flow | −85 | −112 | −113 | −26 | −183 | −356 | −360 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 15 | 44 | 84 | 99 | 121 | 94 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 37 | 300 | 966 | 1,100 | 1,200 | 851 | 1,200 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 156 | 452 | 1,474 | 1,342 | 1,460 | 1,104 | 1,481 |
| Total liabilities | 55 | 206 | 648 | 608 | 478 | 370 | 243 |
| Shareholders' equity | −201 | 246 | 827 | 734 | 981 | 734 | 1,238 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −417,522.2% | −553,166.7% | −757.0% | −555.6% | −46.7% | −654.2% | −274.6% |
| Net margin | −435,144.4% | −810,800.0% | −714.9% | −474.5% | −35.1% | −593.1% | −57.2% |
| Free cash flow margin | −469,561.1% | −467,075.0% | −218.1% | −43.4% | −48.4% | −560.8% | −257.6% |
| Rule of 40 (growth + FCF margin) | — | −467,041.7% | 215,698.5% | −25.9% | 471.6% | −644.0% | −137.6% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −875.4% | −69.1% | −37.1% | −15.5% | −43.9% | −8.1% |
| Return on assets | — | −64.0% | −38.5% | −20.5% | −9.5% | −29.4% | −6.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — |